KalVista Pharmaceuticals (KALV) Stifel 2024 Healthcare Conference summary

Regulatory and product update

• Sebetralstat, an oral on-demand therapy for hereditary angioedema (HAE), is under regulatory review with a PDUFA date set for June 17, 2025, and filings in the US, EU, UK, Singapore, Australia, Switzerland, and a planned filing in Japan by year-end.

• Regulatory interactions have been routine and administrative, with no substantive issues or expected REMS; a 120-day safety update was recently filed.

• Labeling discussions are expected to mirror existing products like Firazyr, with a likely reasonable cap on daily doses but no major safety concerns.

Market landscape and opportunity

• The on-demand HAE market is valued at approximately $900 million, with about 120,000–125,000 units sold annually; branded pricing could push the market to over $1.3 billion.

• Market growth is expected as more patients treat attacks and as poorly controlled prophylaxis users adopt on-demand therapy.

• The payer landscape is managed mainly through prior authorizations and medical exceptions, with step therapy being rare.

Commercial strategy and launch preparation

• The commercial team is fully built out, with field force and payer access managers joining in Q1; high prescribers are being engaged ahead of launch.

• The sales force will consist of about 30–35 reps, targeting a concentrated prescriber base, with total commercial operations around 50 people.

• Uptake is expected to start with a bolus of early adopters, especially poorly controlled prophylaxis users, followed by steady growth.